As you have no idea about future revenue, nor about the value of JVs you have given a very compelling argument which leaves out key data.
Since I admitted upfront that I have no idea about future revenue and I am here to learn, could you please enlighten me and give me your estimation on how much revenue MSB will have to make in order to earn $127 million NPAT per year? While you are at it, please give me the workings on how you derive your revenue estimate.
Also where is your evidence that trial results will be negative?
I never said that the trial results will be negative. This is what I actually said: "If any of the trials' results is negative, then MSB will be in a deeper hole.".
The main word in that sentence is IF.
You see, unlike yourself, I like to consider the possibilities of things going against my prediction. Your track record in predicting MSB's course of events is frankly speaking not that flash:
- US investors will appreciate MSB's potentials, price achieved in Nasdaq listing was at a big discount.
- Teva will not walk away. Teva walked away.
- The financing facility is non-dilutive. It IS dilutive.
If you have any problems putting this in perspective, call the company and get a balanced view. Julie Meldrum is there for Investor relations and she will get back to you if she can't speak immediately.
Thank you for the suggestion, but as the famous American sage likes to say, don't ask a barber if you need a haircut!
Others mentioned in the past that when they contacted investor relations, they were given the latest broker reports to soothe any concerns.
The latest one that was discussed heavily was the Lodge Partners report.
A quick check on HotCopper showed that 5 years ago, they also published a glowing report about the potential of MSB.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)